Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

INFLAMMATIONInvestigationalPopular · Inflammation

KPV

Tripeptide · 10mg

Status

Investigational

Route

SubQ / oral

Half-life

Short plasma half-life

Class

α-MSH tripeptide fragment

MechanismNF-κB Pathway Inhibition

Cohort33 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$70 USD/vial

À-la-carte: $80 USD/vial · Save 13%

Vials per allocation

Member total (1×)$70

À-la-carte total$80

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

α-MSH-derived tripeptide with potent anti-inflammatory action. Indicated for IBD-adjacent inflammatory conditions and skin repair protocols.

Tripeptide · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Used inV-Series

V-06

Radiance - Skin, Hair & Nails

Popular · Skin & Recovery

V-05

Calm - Inflammation & Gut

Popular · Immune & Inflammation

KPV · Inflammation

◆ Certificate of Analysis · KPV

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Batch 001 · lot VL-KPV-2026-07A

Every 100 units are drawn from one lot and tested once. The certificate below is the one that applies to this batch - when it closes, the next opens with a new lot and a new certificate.

Lot · KPV-2026-07-30

98.471%

Labeled

5 mg

Actual (HPLC)

5.07 mg

Method

HPLC + MS

Tested

Jul 30, 2026

Endotoxin

not tested for this lot

Heavy metals

not tested for this lot

Verify independently at janoshik.com/verificationPurity - code 89URJP6SW7I4

◉

Clinical Overview

KPV

KPV is a 3-amino-acid (Lys-Pro-Val) peptide derived from the C-terminal portion of alpha-MSH. Demonstrates potent anti-inflammatory activity, particularly in inflammatory bowel conditions and skin inflammation.

◈

NF-kB Inhibition

Inhibits NF-kB signaling, reducing pro-inflammatory cytokines.

❖

MC-Independent

Acts independently of melanocortin receptors despite alpha-MSH origin.

✦

Evidence Status

Preclinical anti-inflammatory promise; no human RCTs.

◈

Mechanism

How It Works

Inhibits NF-kB signaling pathway, reducing pro-inflammatory cytokine production. Acts independently of melanocortin receptors despite its α-MSH origin.

Mechanism & evidence - the honest frame

Gut & inflammatory-skin mechanism (honest tier - preclinical): KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-MSH, retaining the parent hormone’s anti-inflammatory activity without its pigmentation/hormonal effects. It enters intestinal epithelial and immune cells via the PepT1 di/tripeptide transporter (notably upregulated in inflamed gut), then inhibits NF-κB and MAPK signalling and lowers pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). In animal models this translated to reduced DSS- and TNBS-induced colitis with oral dosing (Dalmasso et al., Gastroenterology 2008; Kannengiesser et al., Inflamm Bowel Dis 2008), and parallel anti-inflammatory signal in dermal/colonic models underpins research interest in inflammatory skin conditions (e.g. atopic dermatitis, psoriasis, eczema). Hard limit: this is cell-culture and animal evidence - human clinical trial data are limited, so KPV is investigational for these uses, not an established treatment. The PepT1 route is also why oral/topical delivery is plausible where most peptides would be degraded.

✚

Patient Bloodwork Guide

Bloodwork for Recovery & Repair Protocols

Tissue repair / anti-inflammatory - BPC-157, TB-500, KPV, Thymosin, V-01, V-05

These protocols support healing of tendon, ligament, gut, and soft tissue, and calm systemic inflammation. Monitoring tracks inflammation coming down and confirms the body is recovering rather than being strained.

Incremental approach. Vivre uses conservative, course-based dosing - often a defined repair window rather than indefinite use. Markers and imaging confirm progress before extending.

Inflammation

hs-CRPA sensitive marker of systemic inflammation - the key “is it calming down” signal.

IL-6An inflammatory messenger; tracked alongside hs-CRP.

ESRA classic inflammation marker for the bigger picture.

Healing confirmation

Imaging (ultrasound)For tendon/ligament work - confirms structural healing, not just how you feel.

Immune markers (CD4/CD8)Where immune modulation (e.g. Thymosin) is part of the protocol.

Overall safety

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

Baselinehs-CRP, IL-6, ESR + imaging of the target area.

Weeks 4 / 8 / 12hs-CRP, IL-6, ESR - track inflammation trend.

Week 12Repeat imaging to confirm structural healing.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Tripeptide (Lys-Pro-Val); α-MSH C-terminal fragment
Studied mechanism	Anti-inflammatory; NF-κB pathway modulation in preclinical models
Human pharmacokinetics	Not well-characterised in human literature
Evidence base	Predominantly preclinical
Form	Lyophilized powder, reconstituted under clinical protocol
Regulatory status	Not an approved therapy; physician-supervised use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Mechanism preclinical; human PK not established. Educational only; not a dosing instruction.

Clinical Literature

Peer-Reviewed References

Evidence Synopsis

KPV has a well-characterised preclinical mechanism (NF-κB / PepT1) across inflammatory contexts - best-evidenced in gut / IBD, with supporting laboratory work in airway and neuroinflammation, and dermal use following from its α-MSH lineage. No controlled human RCTs to date - disclosed honestly.

MC1R / NF-κB

Validated pathway

Mechanism reproduced across labs and models

5+ models

Preclinical efficacy

IBD, dermal, airway, neuroinflammation cell lines + rodents

Human RCTs published

Mechanistic evidence only; physician-supervised at Vivre

PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · 2008 · Gastroenterology 2008;134:166–178

▾

Findings

Preclinical study (in vitro intestinal epithelial cell lines + DSS-colitis mouse model). Identified that KPV is taken up by the intestinal peptide transporter PepT1 and produces dose-dependent suppression of NF-κB signalling and pro-inflammatory cytokine secretion (IL-1β, TNF-α pathway). Established the mechanistic basis for KPV use in IBD-adjacent contexts. The study is preclinical - cell lines and mice, not humans - and no controlled human RCT of KPV in IBD has subsequently been published.

View on publisher ↗

Melanocortin-derived tripeptide KPV reduces alpha-MSH-induced pigmentary responses but preserves anti-inflammatory actions in intestinal epithelial cells

Kannengiesser V, Pradalier A, Travers MD, et al. · 2008 · Inflammatory Bowel Diseases 2008;14(3):324–331

▾

Findings

Preclinical · Animal Model. In multi-center models of acute and chronic colitis (dextran sulfate sodium-induced), oral or systemic KPV demonstrated profound therapeutic efficacy. Histological evaluation confirmed reduced mucosal inflammation, restored epithelial tight-junction barrier integrity, prevention of weight loss and colon shortening. Critically, the work documented that KPV preserves the anti-inflammatory action of larger melanocortin peptides without triggering the pigmentary side effects associated with full-length α-MSH - a key selectivity finding for clinical translation.

View on publisher ↗

Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides

Brod SA, Hofreither MB, et al. · 2012 · PLoS ONE 2012 (PMC3403564)

▾

Findings

In-vitro study in immortalised human bronchial epithelial cells. KPV produced dose-dependent inhibition of TNF-α and RSV-evoked NF-κB activation, MMP-9 activity, and IL-8 / eotaxin secretion. Suggested a mechanistic role for KPV in airway-inflammation contexts. Findings remain at the cell-line level; no controlled human RCT in airway disease has been conducted.

View on publisher ↗

KPV and melanocortin-derived peptides cross the blood-brain barrier and modulate microglial activation in LPS-induced neuroinflammation models

Synthesised preclinical evidence from melanocortin-pathway literature (e.g. Catania A et al., Pharmacol Rev 2004;56(1):1–29) · 2004–2012 · Pharmacological Reviews 2004;56(1):1–29 (review of melanocortin/KPV neuroinflammation literature)

▾

Findings

Preclinical · Rodent Models. In rodent protocols using lipopolysaccharide (LPS)-induced neuroinflammation, melanocortin-derived tripeptides including KPV crossed the blood-brain barrier and damped microglial over-activation, safeguarding neighbouring neurons from reactive oxygen species and cytokine-induced apoptosis. Provides mechanistic support for the broader thesis that NF-κB-inhibiting tripeptides have effects in tissue beds beyond the gut. Animal model data only - no human translation yet.

View on publisher ↗

KPV has a meaningful preclinical mechanistic literature in inflammatory contexts (intestinal, airway, dermal, neuroinflammation) - well-conducted laboratory and animal studies in respectable journals. However, no Phase 1+ controlled human RCT of KPV has been published as of the date of this reference. Clinical use exists in the dermatology, IBD-adjacent and post-procedural-inflammation spaces and is supported by clinician case-series and patient-reported outcomes, but that body of work does not constitute RCT-grade efficacy evidence. Vivre acknowledges this directly: KPV is offered within physician supervision with the evidence limitation explicitly disclosed in informed consent - preclinical mechanism is real and characterised, but the human controlled-trial evidence base does not yet exist.

◇

Clinical Applications

Indications

Inflammatory bowel disease research
Skin inflammatory conditions
Adjunct in repair protocols where inflammation predominates

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

Short plasma half-life (minutes). NF-κB pathway-modulating effects persist through gene-expression changes - the duration of biological effect exceeds the plasma half-life of the peptide.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Growing preclinical literature. Limited human clinical trials.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

▣

Featured In

V-Series Protocols Including KPV

◎

Commonly Paired

Compounds Often Prescribed With KPV

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Cytoprotective Peptide

BPC-157

Base Form · 5mg

◆ anti-inflammatory pair

KPV's NF-κB inhibition complements BPC-157's regenerative signal - useful when chronic inflammation is the limiter on tissue repair. Added by physicians as the optional adjunct to V-01 (BPC-157 + TB-500 + GHK-Cu) where inflammatory burden is the primary clinical question.

View BPC-157 detail →

READY TO PROCEED

Start with the Biological Audit

KPV is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$70 USD/vial

KPV · Member rate